NR1H4 and fatty liver disease: Currently, drug classes suitable for combination, acting with different mechanisms of action targeting hepatic steatosis, inflammation and fibrosis, are FXR agonists, PPARs agonists, thyroid hormone receptor beta agonists, carriers inhibitors (mitochondria pyruvate carrier, sodium/glucose transport protein 2), metabolic enzyme inhibitors [stearoyl-CoA desaturase-1 (SCD-1), acetyl-CoA carboxylase (ACC), hepatic fructokinase], fibroblast growth factor 21 (FGF21) agonists, glucagon-like peptide-1 (GLP-1) receptor agonists, and chemokine receptor (CCR) inhibitors (Dufour et al., 2020).